AI Startup Raises $3.5M to Catch Chronic Disease Before It Strikes
Munich's dehaze uses AI to scan the 97% of patient data doctors never see, targeting earlier chronic disease detection at scale.
Summary
A Munich-based AI startup called dehaze has raised $3.5 million to build a platform that analyzes the vast majority of patient health data that doctors currently never review. The core problem: physicians typically see less than 3% of available patient data before making decisions, and over 31% of chronic conditions go undetected until they are costly or difficult to treat. dehaze's AI scans full patient histories — lab results, prescriptions, past records — to flag early warning signs with explanations clinicians and insurers can act on. Its first customers are health insurers, who bear the financial weight of chronic disease. The company claims its platform could reduce annual health spending by up to 10%, representing hundreds of billions in potential savings globally.
Detailed Summary
Chronic disease is the leading driver of death and healthcare costs worldwide, yet the data needed to catch it early already exists in medical records — it just goes unread. Munich startup dehaze has secured $3.5 million in seed funding to change that, building an AI platform designed to surface early warning signals from the enormous volumes of patient data that clinicians never have time to review.
The scale of the problem is striking. Doctors review less than 3% of available patient data before making clinical decisions. As a result, more than 31% of chronic conditions go undetected at the stage where prevention or low-cost intervention is still possible. By the time many conditions are diagnosed, treatment is more invasive, more complex, and far more expensive. Globally, chronic diseases account for over $8 trillion in annual healthcare spending and roughly 70% of all deaths.
dehaze's platform functions as a continuous analytical layer, scanning full patient records — lab results, imaging, prescriptions, clinical histories — and identifying combinations of signals that suggest emerging risk. Crucially, the system provides explanations alongside its predictions, addressing a major barrier to AI adoption in medicine: the black-box problem. Clinicians and insurers need to understand why a flag was raised, not just that it was.
The company's initial customers are health insurers rather than hospitals, a pragmatic entry point given that payers directly absorb the financial consequences of late-stage chronic disease. dehaze estimates its platform could reduce annual health spending by up to 10% — a figure that, applied to an $8 trillion market, represents structural rather than incremental change.
Caveats apply. The $3.5 million raise is early-stage, the 10% savings claim is forward-looking and unvalidated in peer-reviewed literature, and real-world clinical integration of AI tools remains challenging. Independent validation of detection accuracy and outcomes data will be essential before drawing firm conclusions about efficacy.
Key Findings
- Doctors review under 3% of available patient data, leaving most chronic disease risk signals undetected before decisions are made.
- Over 31% of chronic conditions go undetected at the stage where prevention or affordable treatment is still possible.
- dehaze's AI scans full patient records and provides explainable risk flags, targeting the black-box limitation of medical AI.
- Health insurers are the primary early customers, aligning financial incentives with earlier chronic disease detection.
- The platform claims potential to cut annual health spending by up to 10% across an $8 trillion global chronic disease market.
Methodology
This is a news report covering a startup funding announcement, not a peer-reviewed study. The source, Longevity.Technology, is a credible longevity-focused publication. Claims about detection rates and cost savings are drawn from the company's own statements and have not been independently validated in published clinical research.
Study Limitations
All efficacy and savings figures originate from dehaze's own projections and have not been validated by independent clinical trials or peer-reviewed publications. The platform is early-stage with no publicly available outcome data. Regulatory approval pathways and real-world integration challenges in diverse healthcare systems remain unaddressed in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.